Erectile dysfunction is the inability to maintain an erection sufficient for pleasurable sexual performance. The management of this disorder includes a person’s medical history, sexual history, and psychological history. There are many drugs available for the treatment of erectile dysfunction, including brand name drugs and generic drugs. It is a common medical condition that mainly affects men over the age of 40. Stress and mental health issues can make the problem worse, and physical and psychological problems can also cause erectile dysfunction.

Click Here for Sample Premium Report @

Demand Scenario

Global Erectile Dysfunction Market was USD 4117.1 Million in 2018 and is projected to reach USD 4812.6 Million by 2025 at a CAGR of 2.25% during the forecast period

Growth by region

North America dominated the global erectile dysfunction market, occupying more than 42.6% of the total market share in 2018. The various factors driving the growth of the market are better access to ED treatments and coverage reimbursement for high penile implant post surgeries. Europe is the second largest market while Asia-Pacific is showing the fastest growth due to the rapid evolution of the healthcare sector and the presence of huge opportunities for the development of this market. However, the Middle East and Africa has the minimum market share due to the presence of poor and slow developing countries, especially in the African region. The Middle East holds the major regional market share owing to well-developed technology and high expenditure.

You can buy this report here @

Drivers and Constraints

Growing awareness of the disease, growing willingness of patients to seek medical assistance for disease management, and increasing presence of supportive guidelines are driving the growth. The global erectile dysfunction market is also witnessing a growing demand for low-cost generic drugs, especially in APAC countries such as India and China. The increased risk of sexually transmitted diseases, reduced insurance coverage for the treatment of erectile dysfunction, the growing threat of counterfeit drugs and the presence of social stigma in developing countries are a few factors limiting the rates of penetration.

Request for Report Discounts @

Industry Trends and Updates

In January 2017, Eli Lilly was awarded as the world’s most ethical company. Pfizer Inc., an American global pharmaceutical company headquartered in New York in June 2017, acquired Neksium from AstraZeneca.